Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Stock Forecast

Stock Price Forecast

The 8 analysts that cover Teva Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $37.38, which forecasts a 31.16% increase in the stock price over the next year. The lowest target is $26 and the highest is $45.

Price Target: $37.38 (+31.16%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$26	$37.38	$40	$45
Change	-8.77%	+31.16%	+40.35%	+57.89%

Analyst Ratings

The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	4	4	4	4	4	4
Buy	3	3	5	5	4	4
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	9	9	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Amsellem Piper Sandler	Piper Sandler	Buy Reiterates $40 → $41	Buy	Reiterates	$40 → $41	+43.86%	Mar 4, 2026
Les Sulewski Truist Securities	Truist Securities	Strong Buy Maintains $38 → $42	Strong Buy	Maintains	$38 → $42	+47.37%	Feb 18, 2026
Matt Dellatorre Goldman Sachs	Goldman Sachs	Strong Buy Maintains $36 → $45	Strong Buy	Maintains	$36 → $45	+57.89%	Feb 9, 2026
Glen Santangelo Barclays	Barclays	Buy Maintains $35 → $38	Buy	Maintains	$35 → $38	+33.33%	Jan 30, 2026
Louise Chen Scotiabank	Scotiabank	Buy Maintains $35 → $40	Buy	Maintains	$35 → $40	+40.35%	Jan 29, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

17.11B

Decreased by -0.89%

from 17.26B

Revenue Next Year

17.54B

Increased by 2.51%

from 17.11B

EPS This Year

2.76

Increased by 128.17%

from 1.21

EPS Next Year

3.10

Increased by 12.19%

from 2.76

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	15.88B	14.93B	15.85B	16.54B	17.26B	17.11B	17.54B
Revenue Growth	-4.69%	-6.00%	6.17%	4.41%	4.32%	-0.89%	2.51%
EPS	0.38	-2.20	-0.50	-1.45	1.21	2.76	3.10
EPS Growth	-	-	-	-	-	128.17%	12.19%
Forward PE	-	-	-	-	-	10.32	9.20
No. Analysts	-	-	-	-	-	6	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028
High	17.9B	18.5B
Avg	17.1B	17.5B
Low	16.2B	16.5B

Revenue Growth

Revenue Growth	2026	2027	2028
High	3.9%	8.0%
Avg	-0.9%	2.5%
Low	-6.3%	-3.6%

EPS Forecast

EPS	2026	2027	2028
High	2.97	3.32
Avg	2.76	3.10
Low	2.56	2.80

EPS Growth

EPS Growth	2026	2027	2028
High	145.6%	20.2%
Avg	128.2%	12.2%
Low	112.0%	1.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.